Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Long-Term Deferred Tax of $117.0 million for Q1 2026, up 9.08% year-on-year from $107.2 million in Q1 2025, and down 7.16% on a QoQ basis from $126.0 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 8 years of Long-Term Deferred Tax data on file, last reported at $117.0 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Deferred Tax rose 9.08% year-over-year to $117.0 million; the trailing twelve-month figure through Mar 2026 stood at $117.0 million (up 9.08% YoY), and the FY2025 full-year result was $126.0 million, up 7.8% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $117.0 million, down from $126.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
- The 4-year median for Long-Term Deferred Tax is $107.2 million (2025), against an average of $97.1 million.
- The widest annual swing landed in 2024, when Long-Term Deferred Tax jumped 1056.94%; it then grew 7.8% in 2025.
- A 4-year view of Long-Term Deferred Tax shows it stood at $10.1 million in 2023, then surged by 1056.94% to $116.9 million in 2024, then gained by 7.8% to $126.0 million in 2025, then retreated by 7.16% to $117.0 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $117.0 million (Q1 2026), $126.0 million (Q4 2025), and $98.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.96 Mn |
| Dec 31, 2025 | 125.98 Mn |
| Sep 30, 2025 | 98.56 Mn |
| Jun 30, 2025 | 104.36 Mn |
| Mar 31, 2025 | 107.22 Mn |
| Dec 31, 2024 | 116.86 Mn |
| Dec 31, 2023 | 10.10 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Sep 30, 2010 | 8.57 Mn |
| Jun 30, 2010 | 8.67 Mn |
| Dec 31, 2009 | 8.56 Mn |